| Dr Stephen M Gross, OD | |
|
166 Lindberg Ave, Atmore, AL 36502-3206 | |
| (251) 368-8767 | |
| (251) 368-4565 |
| Full Name | Dr Stephen M Gross |
|---|---|
| Gender | Male |
| Speciality | Optometry |
| Experience | 43 Years |
| Location | 166 Lindberg Ave, Atmore, Alabama |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1831112317 | NPI | - | NPPES |
| 529503380 | Medicaid | AL |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | S486TA041 (Alabama) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Coastal Eye Care Llc | 9830470335 | 2 |
News Archive
A prospective study recently published in the journal Cephalalgia, the official journal of the International Headache Society, extends the idea behind cluster headache chronicity.
Novartis Pharmaceuticals Corporation announced today that the results of a Phase III study of SOM230 (pasireotide) showed a reduction in cortisol levels in patients with Cushing's disease, a condition in which a benign (non-cancerous) pituitary tumor causes the adrenal glands to produce excess cortisol and can be fatal. Results will be presented at the 14th Congress of the European Neuroendocrine Association (ENEA).
New research presented at the American Diabetes Association's 70th Scientific Sessions in Orlando, Florida on June 27, 2010 suggests that a medical food developed by Metagenics, Inc. called UltraMeal® PLUS 360° enhances the cardiovascular disease (CVD) risk-lowering benefits of a Mediterranean-style low-glycemic-load diet.
Commonwealth Biotechnologies, Inc. ("CBI") is pleased to announced it has entered into a revised and binding definitive share purchase agreement to acquire the parent of Shanghai-based GL
BioPharmX Corporation today announced the closing of its previously announced underwritten public offering of 3,636,364 shares of its common stock at a price to the public of $2.75 per share.
› Verified 3 days ago
| Provider Name | Helton Vision Associates Pc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1467504100 PECOS PAC ID: 6901857796 Enrollment ID: O20050209000644 |
News Archive
A prospective study recently published in the journal Cephalalgia, the official journal of the International Headache Society, extends the idea behind cluster headache chronicity.
Novartis Pharmaceuticals Corporation announced today that the results of a Phase III study of SOM230 (pasireotide) showed a reduction in cortisol levels in patients with Cushing's disease, a condition in which a benign (non-cancerous) pituitary tumor causes the adrenal glands to produce excess cortisol and can be fatal. Results will be presented at the 14th Congress of the European Neuroendocrine Association (ENEA).
New research presented at the American Diabetes Association's 70th Scientific Sessions in Orlando, Florida on June 27, 2010 suggests that a medical food developed by Metagenics, Inc. called UltraMeal® PLUS 360° enhances the cardiovascular disease (CVD) risk-lowering benefits of a Mediterranean-style low-glycemic-load diet.
Commonwealth Biotechnologies, Inc. ("CBI") is pleased to announced it has entered into a revised and binding definitive share purchase agreement to acquire the parent of Shanghai-based GL
BioPharmX Corporation today announced the closing of its previously announced underwritten public offering of 3,636,364 shares of its common stock at a price to the public of $2.75 per share.
› Verified 3 days ago
| Provider Name | Coastal Eye Care Llc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1710433271 PECOS PAC ID: 9830470335 Enrollment ID: O20161221000455 |
News Archive
A prospective study recently published in the journal Cephalalgia, the official journal of the International Headache Society, extends the idea behind cluster headache chronicity.
Novartis Pharmaceuticals Corporation announced today that the results of a Phase III study of SOM230 (pasireotide) showed a reduction in cortisol levels in patients with Cushing's disease, a condition in which a benign (non-cancerous) pituitary tumor causes the adrenal glands to produce excess cortisol and can be fatal. Results will be presented at the 14th Congress of the European Neuroendocrine Association (ENEA).
New research presented at the American Diabetes Association's 70th Scientific Sessions in Orlando, Florida on June 27, 2010 suggests that a medical food developed by Metagenics, Inc. called UltraMeal® PLUS 360° enhances the cardiovascular disease (CVD) risk-lowering benefits of a Mediterranean-style low-glycemic-load diet.
Commonwealth Biotechnologies, Inc. ("CBI") is pleased to announced it has entered into a revised and binding definitive share purchase agreement to acquire the parent of Shanghai-based GL
BioPharmX Corporation today announced the closing of its previously announced underwritten public offering of 3,636,364 shares of its common stock at a price to the public of $2.75 per share.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Stephen M Gross, OD 10184 Eastern Shore Blvd, Ste A, Spanish Fort, AL 36527-5814 Ph: (251) 368-8767 | Dr Stephen M Gross, OD 166 Lindberg Ave, Atmore, AL 36502-3206 Ph: (251) 368-8767 |
News Archive
A prospective study recently published in the journal Cephalalgia, the official journal of the International Headache Society, extends the idea behind cluster headache chronicity.
Novartis Pharmaceuticals Corporation announced today that the results of a Phase III study of SOM230 (pasireotide) showed a reduction in cortisol levels in patients with Cushing's disease, a condition in which a benign (non-cancerous) pituitary tumor causes the adrenal glands to produce excess cortisol and can be fatal. Results will be presented at the 14th Congress of the European Neuroendocrine Association (ENEA).
New research presented at the American Diabetes Association's 70th Scientific Sessions in Orlando, Florida on June 27, 2010 suggests that a medical food developed by Metagenics, Inc. called UltraMeal® PLUS 360° enhances the cardiovascular disease (CVD) risk-lowering benefits of a Mediterranean-style low-glycemic-load diet.
Commonwealth Biotechnologies, Inc. ("CBI") is pleased to announced it has entered into a revised and binding definitive share purchase agreement to acquire the parent of Shanghai-based GL
BioPharmX Corporation today announced the closing of its previously announced underwritten public offering of 3,636,364 shares of its common stock at a price to the public of $2.75 per share.
› Verified 3 days ago
Poarch Band Of Creek Indians Dba Premier Family Eye Care Optometrist Medicare: Not Enrolled in Medicare Practice Location: 5811 Jack Springs Rd, Atmore, AL 36502 Phone: 251-446-3937 Fax: 251-368-0805 | |
Dr. David J Helton, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 166 Lindberg Ave, Atmore, AL 36502 Phone: 251-368-8767 | |
Monroeville Eye Care Optometrist Medicare: Medicare Enrolled Practice Location: 166 Lindberg Ave, Atmore, AL 36502 Phone: 251-368-8767 Fax: 251-368-4565 | |
Dr. John Taylor Cooper, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 212 S Main St, Atmore, AL 36502 Phone: 251-368-8558 |